Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
about
Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICAHER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesPlasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix.PI3K/Akt pathway restricts epithelial adhesion of Dr + Escherichia coli by down-regulating the expression of decay accelerating factor.Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infectionRole of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients.Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis.The role of complement in tumor growthComplement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration.On the intersections of basic and applied research in xenotransplantation.Therapeutic vaccines for gastrointestinal cancers.Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical diseaseCombined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancerSelective aryl hydrocarbon receptor modulator-mediated repression of CD55 expression induced by cytokine exposureAnaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia.Role of transcription factor Sp1 and RNA binding protein HuR in the downregulation of Dr+ Escherichia coli receptor protein decay accelerating factor (DAF or CD55) by nitric oxideExpression of membrane cofactor protein (MCP, CD46) in human liver diseases.Nitric oxide induces segregation of decay accelerating factor (DAF or CD55) from the membrane lipid-rafts and its internalization in human endometrial cells.Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.Modulation of protective T cell immunity by complement inhibitor expression on tumor cells.Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.Protein engineering to target complement evasion in cancer.Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.The Afa/Dr adhesins of diffusely adhering Escherichia coli stimulate interleukin-8 secretion, activate mitogen-activated protein kinases, and promote polymorphonuclear transepithelial migration in T84 polarized epithelial cells.Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.CD55 is over-expressed in the tumour environment.CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis.Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.Beyond the Role of CD55 as a Complement Component.Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer.
P2860
Q24292262-1A8905CA-3638-43BE-8E5C-54B0B5306259Q26822730-66A59C9A-C76B-43C5-B67B-73C5C17D4724Q33453474-2786D595-F34E-4BF8-BA40-8451417F5259Q33896695-4672CB93-BB99-4C45-A105-921F49EB53CFQ34257818-E76F5D13-5E9F-4411-8DCF-81A8FC42770EQ34425723-9EEA69C2-1BF0-4C65-BC3D-32F936B4EFE8Q35021471-F0231C03-CF33-4146-9537-07613794E150Q35231345-8DD5284A-77BC-4963-8DB9-A6CA5AF0F105Q35536219-E7EB3EF7-AEE8-4847-9AE6-BE8BE8342EBAQ35687758-1D666F06-BE01-4B3A-932E-9CE7D68A63BAQ35691248-A8156E74-6E06-4E92-890C-42FAF4566E5CQ35764045-7CAB7446-0503-4679-AFB5-FD75C4065926Q35914730-82BB9DAC-ED3A-414B-B405-75457BC32E01Q36057882-578DE3CC-1E6A-48D4-9C5C-C11CFE88AB3DQ36105385-5B6AC51F-8E49-4C01-8C39-5C76AA6A0639Q36338990-8A9556E0-B94F-4C95-84D8-1B80F3326B3FQ36513623-0BFEF8E0-EAAE-4B6C-84CF-7BB21FFE6FFAQ36572584-9A6B32DB-9048-4595-9639-4BB5A1827A28Q36640857-FED78A55-EBE4-4F55-8858-7978D346F7DAQ36966192-DF4ED16F-8518-4C5E-803F-ADFD2AA1F1B3Q37189823-70D1266F-3BB4-40CC-9BED-66FB24AF37F4Q37189831-5E0A0301-47C5-4D46-BC7F-9D6B9A30DF2EQ37372067-E1EDE291-2FAF-428B-B899-47CAA09A6457Q38163242-87E14D37-52F8-443E-8592-7DD82C09C73FQ38291696-083B7316-4F9F-458F-9B55-DB1104448F19Q38962764-0E22B138-BAA6-4B10-91A6-B7DE6112928DQ39317804-AD897D0F-4317-42B5-B0DE-A1EC310E194EQ39730178-C1CBFCF5-F175-4A19-8728-7E3C7771C990Q40863583-55120195-D5E9-428A-A5A3-E4C9EE39C6CCQ40975372-479F9003-72F4-450B-A3F8-D2F445409B46Q41770177-21646194-F3CF-48D4-B339-2B6206EDEABDQ43144337-ECD6FA3D-C722-48AF-8A44-E1C797A616F7Q49672464-254381B3-A56D-4595-A09B-89C462D5751DQ50338802-4B3EEF19-A622-4051-96C2-17C0F0422D78Q53942590-CB90AFC8-AF3D-4E97-A168-69D88F7D02ACQ55240185-EDED292C-3795-452C-ACC7-4D050AD2BAFA
P2860
Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Human carcinomas variably expr ...... factor), and CD59 (protectin).
@ast
Human carcinomas variably expr ...... factor), and CD59 (protectin).
@en
type
label
Human carcinomas variably expr ...... factor), and CD59 (protectin).
@ast
Human carcinomas variably expr ...... factor), and CD59 (protectin).
@en
prefLabel
Human carcinomas variably expr ...... factor), and CD59 (protectin).
@ast
Human carcinomas variably expr ...... factor), and CD59 (protectin).
@en
P2093
P2860
P1476
Human carcinomas variably expr ...... factor), and CD59 (protectin).
@en
P2093
Cherwitz DL
Dalmasso AP
Niehans GA
P2860
P304
P407
P577
1996-07-01T00:00:00Z